Branching morphogenesis of the metanephric kidney is critically dependent on the delicate orchestration of diverse cellular processes including proliferation, apoptosis, migration, and differentiation. Sphingosine-1-phosphate (S1P) is a potent lipid mediator influencing many of these cellular events. We report increased expression and activity of both sphingosine kinases and S1P phosphatases during development of the mouse metanephric kidney from induction at E11.5 to maturity. Sphingosine kinase activity exceeded S1P phosphatase activity in embryonic kidneys resulting in a net accumulation of S1P, while kinase and phosphatase activities were similar in adult tissue resulting in reduced S1P content. Sphingosine kinase expression was greater in the metanephric mesenchyme than in the ureteric bud while the S1P phosphatase, SPP2, was expressed at greater levels in the ureteric bud. Treatment of cultured embryonic kidneys with sphingosine kinase inhibitors resulted in a dose-dependent reduction of ureteric bud tip numbers and increased apoptosis. Exogenous S1P rescued kidneys from apoptosis induced by kinase inhibitors. Ureteric bud tip number was unaffected by exogenous S1P in kidneys treated with N,N-dimethylsphingosine, though tip number increased in those treated with D,L-threo-dihydrosphingosine. S1P 1 and S1P 2 were the predominant S1P receptors expressed in the embryonic kidney. S1P 1 expression increased during renal development while expression of S1P 2 decreased, and both receptors were expressed predominantly in the metanephric mesenchyme. These results demonstrate dynamic regulation of S1P homeostasis during renal morphogenesis, and suggest that differential expression of S1P metabolic enzymes and receptors provide a novel mechanism contributing to the regulation of kidney development. 
INTRODUCTION
Development of the metanephric kidney is a highly complex event orchestrated by numerous factors regulating proliferation, migration, and differentiation of individual cell types to form the functional kidney. This process is initiated by induction of the ureteric bud, an outgrowth of the Wolffian duct, by the metanephric mesenchyme. Subsequent branching of the ureteric bud induces mesenchymal-to-epithelial transformation and nephron formation. Inductive interactions between the ureteric bud epithelia and the metanephric mesenchyme are mediated by a multitude of stimulatory and inhibitory factors (7, 42) . Failure of mechanisms regulating normal kidney development can result in a variety of congenital defects and may contribute to nephron deficiencies leading to development of hypertension and renal failure.
Sphingosine-1-phosphate (S1P) is a potent bioactive lipid that functions both as an intracellular second messenger promoting cell survival and proliferation, and as a ligand for G-protein-coupled cell surface receptors (S1PRs) to influence migration and differentiation. S1P has a powerful influence on developmental processes and recent studies have clearly demonstrated that S1P signaling is essential to the development of vascular and neural systems as well as morphogenesis of the heart and pancreas (3, 9, 31, 49) . The role of S1P in regulation of kidney development, however, has not been examined.
Within the cell, S1P is in dynamic balance with its precursors, ceramide and sphingosine, forming what is termed the 'sphingolipid rheostat' (43). Ceramide has an opposing action to S1P, inhibiting growth and promoting apoptosis (39). The balance between S1P and ceramide therefore determines whether cells undergo apoptosis or proliferation. Secreted S1P further provides autocrine and paracrine signals through activation of five known S1PRs (S1P [1] [2] [3] [4] [5] ). S1PR activation influences a variety of downstream signaling pathways including Ca 2+ mobilization, cAMP regulation, inositol phosphate metabolism, activation of PI3K, Akt, ERK, and phospholipase C (15) . S1P
concentration is a primary determinant of all subsequent signaling events, both intracellular and S1PR-mediated. Regulation of S1P homeostasis is therefore of critical importance to numerous downstream signaling events.
S1P is produced by the action of sphingosine kinases, SphK1 and SphK2, which differ in tissue distribution, subcellular localization, and substrate specificity (20, 24, 26).
Cellular S1P levels are further regulated by the activities of S1P phosphatases (SPPs) and S1P lyase (SPL), which dephosphorylate S1P to sphingosine or hydrolyze S1P to phosphoethanolamine and hexadecanol, respectively. Two mammalian SPPs have been identified that are highly specific for sphingosine phosphates (30, 33). Both are thought to function in the intracellular regulation of S1P and ceramide concentrations, or the 'sphingolipid rheostat', and therefore play a critical role in the determination of cell fate 6 and function of S1P during kidney development, however, has not been previously reported. The current studies demonstrate mRNA expression of S1P metabolic enzymes and receptors during development of the mouse metanephric kidney. SphK and SPP activities also were examined in developing mouse kidneys and the resulting effect on tissue S1P level was determined. To assess the impact of S1P homeostasis on kidney morphogenesis, kidneys were cultured with a variety of SphK inhibitors. Results demonstrate that S1P homeostasis is dynamically regulated during renal development by differential expression of S1P metabolic enzymes and that SphK activity is essential for kidney branching morphogenesis. Results further indicate that S1P receptor expression is also differentially regulated in the developing mouse kidney. S1P quantification. S1P concentration in embryonic and adult kidneys was assessed by S1P ELISA (Echelon Inc., Salt Lake City, UT). Kidney homogenates prepared in SphK buffer described above were applied to the ELISA plate at 30 µg protein/well. Exogenous S1P (Sigma) was prepared in suspension with 4 mg/ml BSA in PBS and added to culture media at 1:100 dilution (10 µM final). Vehicle controls were treated with EtOH ± BSA only.
MATERIALS AND METHODS

Animals
Immunofluorescence.
To determine ureteric bud tip number, whole mount Apoptosis studies. Apoptosis was assessed by DNA fragmentation analysis similar to previously described methods (38). Kidneys were washed twice with PBS, pelleted, and resuspended in 100 µl lysis buffer (10 mM EDTA, 20 mM Tris, pH 7.5, 0.5% Triton X-100). Samples were incubated on ice for 30 min with occasional inversion and centrifuged at 13,000x g for 20 min at 4°C. Lysates were then incubated at 37°C for 1 h with 0.2 mg/ml DNase-free RNase followed by 0.2 mg/ml proteinase K at 50°C for 2 h.
DNA was precipitated at -20°C with an equal volume of isopropanol and 0.05 volume 5 M NaCl. Following centrifugation at 13,000x g for 15 min at 4°C, the DNA pellet was washed twice with 75% ethanol and dissolved in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.4). DNA fragmentation was analyzed by electrophoresis in a 1.5% agarose gel.
Statistical analysis. Data are reported as means ± SE. Comparisons between groups
were evaluated by unpaired Student's t-test. Statistical significance was identified as P < 0.05.
RESULTS
Expression and activity of S1P metabolic enzymes. Transcriptional expression of genes encoding S1P metabolic enzymes was examined by real-time RT-PCR from induction of kidney morphogenesis at E11.5 through maturation. Fig. 1 illustrates developmental changes in renal expression of sphingosine kinases, SphK1 and SphK2, and S1P catabolic enzymes (SPP1, SPP2, and SPL). Expression of both SphKs and SPPs increased as development progressed (Fig. 1A) . Expression of SphKs increased approximately 4-fold between induction at E11 and maturity, with increased expression of SphK1 preceding SphK2 at postnatal day 4. SphK2 was expressed at greater levels than SphK1 in both embryonic and mature kidneys (Fig. 1B) . Expression of S1P phosphatases increased to a greater extent than SphKs (Fig. 1A) . SPP2 expression increased approximately 8-fold and SPP1 increased more than 50-fold between age E11.5
and adult. SPP2 expression exceeded SPP1 in embryonic kidneys, while SPP1 was the predominant phosphatase in mature kidneys (Fig. 1B) . SPL expression was relatively constant as development progressed, with a 2-fold increase observed at postnatal day 4.
Importantly, the relative expression of kinases to catabolic enzymes changed as the kidney matured (Fig. 1B) . In embryonic kidneys, SphK2 was expressed at higher levels than either SPPs or SPL, while in mature kidneys SPP expression was equal to or greater than expression of SphKs. Distribution of S1P metabolic enzyme expression within the embryonic kidney was further examined by RT-PCR following microdissection of the ureteric bud and metanephric mesenchyme (Fig. 2) . Both SphKs and SPL were more highly expressed in the metanephric mesenchyme, while SPP2 expression was greater in the ureteric bud. Gene expression in the ureteric bud and metanephric mesenchyme were normalized to 18S rRNA because β-actin was found to be more highly expressed in metanephric mesenchyme. GDNF expression is illustrated as both a positive control and for reference.
We examined SphK and SPP activities as well as S1P concentrations in embryonic (E14.5) and adult kidneys to determine whether the observed increases in mRNA expression result in corresponding changes in enzyme activity and a shift of S1P homeostasis (Table 1) . SphK activity was fairly robust in adult kidney extracts at 122 ± 23 pmol/min/mg cellular protein and similar to previously reported results (12, 36).
SphK activity in E14.5 kidneys was approximately 5-fold lower than observed for adult tissue at 21 ± 6 pmol/min/mg protein, reflecting differences observed in mRNA expression. SPP activity also mirrored changes in expression and was minimally detectable in kidneys at age E14.5 (2 ± 2 pmol/min/mg protein), while kidneys from adult mice exhibited SPP activity equal to or greater than SphK activity. S1P concentration assessed in embryonic and adult kidneys reflected the differential activities of S1P metabolic enzymes. S1P was relatively abundant at 287.7 ± 28.5 pmol/mg cellular protein in kidneys isolated at age E14.5, when activity of SphKs exceeded SPPs, while S1P was not detectable in adult tissue.
SphK inhibitors reduce ureteric bud tip number in cultured kidneys.
Branching of the ureteric bud was examined in kidneys isolated at gestational day E11.5 and cultured for 3 days with increasing concentrations of the SphK inhibitor, N,N-dimethylsphingosine (DMS), or vehicle only (Fig. 3) . Cytokeratin immunostaining shows numerous, symmetrical branch points and ampullary tips in vehicle controls ( Fig. 3A ; left) and a dramatic reduction in tip number with increasing concentrations of DMS ( Fig. 3A ; right).
Tip number was reduced by approximately 50% and 70% in the presence of 20 μM and 50 μM DMS, respectively (Fig. 3B) . 10 μM DMS did not have a significant effect on tip number at 3 days of treatment (not shown). After 6 d of treatment, however, reduced ureteric bud branching was readily apparent with lower concentrations of DMS (Fig. 3C) .
DNA fragmentation analysis demonstrated increased apoptosis in kidneys treated with 20
and 50 μM DMS (Fig. 4) . Apoptosis appeared equally distributed between the ureteric bud and mesenchyme in DMS-treated kidneys following TUNEL staining (not shown).
Examination of DMS-treated kidneys by TUNEL staining did not reveal any specificity of apoptosis localization to ureteric bud or mesenchyme tissue. Addition of 10 μM exogenous S1P reduced the amount of DNA laddering compared to DMS treatment alone (Fig. 4) . Exogenous S1P did not affect ureteric bud tip number in kidneys treated with or without DMS (not shown).
The effect of two novel SphK inhibitors, F-12509A and B-5354c, were tested to exclude the possibility of nonspecific effects associated with DMS treatment. F-12509A
and B-5354c are structurally distinct from sphingosine and act as competitive and noncompetitive inhibitors, respectively (21, 22). Ureteric bud tip number was dosedependently reduced in kidneys cultured in the presence of either of these inhibitors (Table 2) . D,L-threo-dihydrosphingosine (DHS), a selective inhibitor of SphK1, also dose-dependently inhibited ureteric bud branching (Fig. 5) . In contrast to kidneys treated with DMS, addition of exogenous S1P increased the number of ureteric bud tips in kidneys treated with DHS. Kidneys treated with 20 μM DHS plus exogenous S1P exhibited tip numbers similar to untreated kidneys, and kidneys treated with 50 μM DHS plus S1P had a significantly greater number of tips compared to kidneys treated with DHS alone. Exogenous S1P also prevented apoptosis in DHS-treated kidneys similar to results obtained with DMS (not shown).
Differential S1PR expression during kidney development. Expression of S1P
receptors was examined by quantitative RT-PCR in embryonic and mature kidneys (Fig.   6A ). S1PR expression in the kidney was dependent on gestational age. S1P 1 expression increased throughout kidney development and was the most highly expressed of the examined receptors in the adult kidney. Expression of S1P 2 was approximately equal to S1P 1 in kidneys isolated at age E11.5 and decreased toward maturity. Therefore, embryonic kidneys expressed both S1P 1 and S1P 2 while adult tissue expressed predominantly S1P 1 . Low levels of expression were also observed for S1P 3 and S1P 4 during early stages of kidney morphogenesis and S1P 4 expression increased in mature kidneys, while S1P 5 was undetectable in either embryonic or mature kidneys.
Comparison of S1PR expression in mechanically separated ureteric bud and metanephric mesenchyme revealed differential expression of S1PRs within the developing kidney (Fig. 6B) . Expression of both S1P 1 and S1P 2 was greater in the metanephric mesenchyme than in the ureteric bud.
DISCUSSION
This study demonstrates a dramatic shift in S1P homeostasis during kidney morphogenesis regulated by differential expression and activity of S1P metabolic enzymes. Despite lower SphK levels during early stages of kidney development, a near complete absence of S1P catabolism permits retention of S1P produced by SphKs.
Furthermore, both SphK isotypes were expressed at greater levels in the metanephric mesenchyme, while SPP2 was more highly expressed in the ureteric bud. These results suggest that S1P is produced in greater amounts in the mesenchyme while S1P is depleted in the ureteric bud, generating an S1P gradient inclined toward the mesenchyme which may contribute to signals promoting ureteric bud outgrowth and mesenchyme survival. Indeed, SphK activity was essential for branching morphogenesis as SphK inhibition prevented ureteric bud branching and induced apoptosis in cultured metanephric kidneys. SPP expression and activity increased to a much greater extent than SphKs as development progressed, resulting in rates of S1P dephosphorylation equal to or greater than S1P production and a net reduction of S1P content in mature kidneys. Studies of sphingolipid content in kidneys of neonatal and adult rats found highest concentrations of S1P during the neonatal period that decreased with age, while ceramide and sphingomyelin content increased with age (11). Although these studies examined S1P content postnatally, the results are consistent with our findings of increased SPP activity and lower S1P content in mature kidneys. Regulation of S1P concentration by differential expression of S1P phosphatases poses intriguing possibilities for the establishment of S1P concentration gradients. SPP activity has also been reported to influence S1P secretion and may therefore contribute to the regulation of S1PR signaling activity (17) . Further studies examining localized SPP expression and development of knockout mice deficient of SPP activity will undoubtedly shed light on the function of these enzymes during development. Relatively more is known about the regulation of SPL and its role in development (5). SPL is a transcriptional target of PDGF and SPL knockout mice display phenotypes consistent with PDGF signaling defects including congenital abnormalities in vascular, skeletal, and renal development (41). In the kidney, development of glomerular structures appears to be the primary site of disruption in SPL knockout mice and increased SPL expression during later stages of kidney development is consistent with the timing of glomerular development. S1P 1 and S1P 2 were expressed at approximately equal levels in the embryonic kidney and both were predominately expressed in the metanephric mesenchyme. S1PRs regulate Rho GTPases and downstream cytoskeletal dynamics. S1P 1 activates Rac and is associated with increased cell motility, while S1P 2 activates Rho and inhibits both Rac activity and cell motility (34). Differential expression of these two S1PRs can therefore result in opposite responses to exogenous S1P. Several recent studies also indicate that cross-talk between S1PRs and growth factor receptors can modulate growth factorinduced cellular responses, providing another level of interaction between these two signaling pathways (6, 10, 45, 46). μM exogenous S1P. Tip numbers were determined by wholemount immunofluorescence.
Values are means ± SE, n = 8 for each group. *P < 0.01 compared with vehicle control; # P < 0.05 compared with DHS alone. Values are means ± SE. *P < 0.05, **P < 0.00001 compared with vehicle control. Numbers of kidneys for each treatment are indicated in parentheses.
